We recently published our article 5 Best Cheap AI Medicine Stocks to Buy Now. To read the full article, head on to 10 Best Cheap AI Medicine Stocks to Buy Now. In this piece, we take a closer look at Certara Inc. (NASDAQ:CERT) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.
Interestingly, the term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.
Why Medicine Could Be AI’s Next Major Market
Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.
Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.
These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.
A Low Share Price Does Not Always Mean Cheap
A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.
The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.
Finding the Best AI Medicine Stocks
This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.
The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.
5 Best Cheap AI Medicine Stocks to Buy Now
4. Certara Inc. (NASDAQ:CERT)
Certara, Inc. (NASDAQ: CERT) reaches fourth place as one of the more financially established AI drug-development stocks. At approximately $7.94 per share and a market capitalization near $1.2 billion, it offers exposure to pharmaceutical research at a valuation below many healthcare software businesses.
The company provides biosimulation, predictive analytics and regulatory software used throughout the drug-development process. Its systems help researchers model how a medicine may behave inside the human body, select appropriate doses and design clinical trials more efficiently.
Biosimulation does not eliminate the need for laboratory experiments or human trials, but it can help researchers make better decisions before committing enormous amounts of capital. This is particularly important because bringing a single medicine to market can cost billions of dollars when failed programs and years of research are included.
Artificial intelligence can strengthen these capabilities by identifying patterns across clinical and biological information. Pharmaceutical customers may use the platform to narrow down potential treatments, improve trial designs and prepare regulatory submissions.
Second-quarter 2026 revenue reached $93.3 million. Software revenue grew 4% to $48.8 million, while services revenue declined 3% to $44.5 million. Total growth was only 1%, which explains part of the stock’s low valuation. Management nevertheless reaffirmed full-year revenue guidance, while its broader outlook called for an adjusted EBITDA margin of approximately 30% to 32%. The quarterly figures and guidance were provided through the official earnings release.
Slow growth is the main weakness, but the company has an established customer base and a business model that does not depend on one clinical trial. It can potentially benefit from rising pharmaceutical research activity regardless of which individual drug succeeds.
The shares may appeal to investors looking for an undervalued AI healthcare stock with stronger commercial foundations than most early-stage biotechnology names. It is unlikely to produce an overnight fortune, but improving software growth could lead to a meaningful valuation recovery.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
